# Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant

> **NCT00472329** · PHASE2 · UNKNOWN · sponsor: **Colorado Blood Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- Graft Failure

## Interventions

- **PROCEDURE:** Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors
- **DRUG:** fludarabine
- **PROCEDURE:** TBI

## Key facts

- **NCT ID:** NCT00472329
- **Lead sponsor:** Colorado Blood Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-03
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2014-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472329, "Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00472329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*